Amneal Pharmaceuticals, Inc. (AMRX) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
, |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 26 | 248 | 341 | 151 | 213 | ||||
| Cash and cash equivalents | 26 | 248 | 341 | 151 | 213 | ||||
| Restricted cash and investments | 9 | 9 | 6 | 2 | 5 | ||||
| Receivables | 775 | 707 | 669 | 636 | 529 | ||||
| Inventory, net of allowances, customer advances and progress billings | 531 | 489 | 491 | 381 | 457 | ||||
| Inventory | 531 | 489 | 491 | 381 | 457 | ||||
| Prepaid expense | 42 | 41 | 34 | 35 | 38 | ||||
| Contract with customer, asset, after allowance for credit loss | 2 | 1 | 2 | 1 | 2 | ✕ | |||
| Other undisclosed current assets | 27 | 25 | 8 | 4 | 41 | ||||
| Total current assets: | 1,412 | 1,520 | 1,552 | 1,210 | 1,287 | ||||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 64 | 59 | 61 | ✕ | ✕ | ||||
| Operating lease, right-of-use asset | 56 | 60 | 59 | 70 | ✕ | ✕ | |||
| Property, plant and equipment | 470 | 514 | 478 | 478 | 544 | ||||
| Intangible assets, net (including goodwill) | 1,695 | 1,760 | 1,827 | 1,802 | 2,081 | ||||
| Goodwill | 599 | 593 | 523 | 420 | 426 | ||||
| Intangible assets, net (excluding goodwill) | 1,096 | 1,167 | 1,305 | 1,383 | 1,655 | ||||
| Other noncurrent assets | 103 | 21 | 32 | 44 | 68 | ||||
| Other undisclosed noncurrent assets | 63 | 373 | |||||||
| Total noncurrent assets: | 2,388 | 2,420 | 2,454 | 2,456 | 3,066 | ||||
| TOTAL ASSETS: | 3,799 | 3,940 | 4,006 | 3,666 | 4,353 | ||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 538 | 583 | 614 | 507 | 514 | ||||
| Taxes payable | ✕ | ✕ | 3 | 6 | 9 | ||||
| Employee-related liabilities | ✕ | ✕ | 62 | 59 | 36 | 77 | |||
| Accounts payable | 166 | 131 | 153 | 103 | 115 | ||||
| Accrued liabilities | 131 | 72 | 80 | 77 | 66 | ||||
| Other undisclosed accounts payable and accrued liabilities | 241 | 316 | 316 | 283 | 257 | ||||
| Debt | 30 | 31 | 44 | 21 | 21 | ||||
| Estimated litigation liability | 107 | ||||||||
| Due to related parties | 2 | 48 | 8 | 6 | 18 | ||||
| Other undisclosed current liabilities | 75 | 15 | 11 | 15 | 0 | ||||
| Total current liabilities: | 753 | 677 | 677 | 550 | 554 | ||||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 2,592 | 2,680 | 2,735 | 2,609 | 2,670 | ||||
| Long-term debt, excluding current maturities | 2,592 | 2,680 | 2,735 | 2,609 | 2,631 | ||||
| Capital lease obligations | ✕ | ✕ | ✕ | ✕ | ✕ | 39 | |||
| Liabilities, other than long-term debt | 147 | 87 | 86 | 40 | 39 | ||||
| Estimated litigation liability | 49 | ||||||||
| Due to related parties | 10 | 48 | |||||||
| Other liabilities | 87 | 39 | 86 | 40 | 39 | ||||
| Other undisclosed noncurrent liabilities | 99 | 112 | 151 | 120 | 194 | ||||
| Total noncurrent liabilities: | 2,838 | 2,879 | 2,972 | 2,769 | 2,903 | ||||
| Total liabilities: | 3,590 | 3,556 | 3,649 | 3,319 | 3,456 | ||||
| Temporary equity, carrying amount | 25 | 17 | 12 | ||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | 298 | 360 | 303 | 232 | 505 | ||||
| Common stock | 0 | ||||||||
| Additional paid in capital | 692 | 658 | 628 | 607 | 530 | ||||
| Accumulated other comprehensive income (loss) | 10 | (25) | (41) | (0) | (8) | ||||
| Accumulated deficit | (406) | (276) | (287) | (378) | (21) | ||||
| Receivable from shareholders or affiliates for issuance of capital stock | (0) | ||||||||
| Other undisclosed equity, attributable to parent | 3 | 3 | 3 | 3 | 3 | ||||
| Equity, attributable to noncontrolling interest | (114) | 7 | 42 | 115 | 392 | ||||
| Total equity: | 184 | 367 | 345 | 347 | 896 | ||||
| TOTAL LIABILITIES AND EQUITY: | 3,799 | 3,940 | 4,006 | 3,666 | 4,353 | ||||
Income Statement (P&L) ($ in millions)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2,212 | 2,094 | 1,993 | 1,626 | 1,663 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (1,416) | (1,302) | (1,330) | (1,147) | (947) | |||
| Other undisclosed gross profit | (11) | (23) | (35) | (126) | ||||
| Gross profit: | 785 | 769 | 628 | 353 | 716 | |||
| Operating expenses | (884) | (603) | (537) | (602) | (533) | |||
| Other operating income, net | 4 | |||||||
| Other undisclosed operating income (loss) | 0 | (14) | (203) | |||||
| Operating income (loss): | (95) | 153 | 91 | (249) | (20) | |||
| Nonoperating income (expense) | (153) | (121) | (127) | 28 | (183) | |||
| Investment income, nonoperating | 0 | 7 | (3) | |||||
| Gain (loss), foreign currency transaction, before tax | (12) | (0) | 16 | (5) | (20) | |||
| Interest and debt expense | (5) | (5) | (9) | (6) | (6) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (253) | 27 | (44) | (227) | (209) | |||
| Other undisclosed income from continuing operations before income taxes | 5 | 5 | 9 | 6 | 6 | |||
| Income (loss) from continuing operations before income taxes: | (248) | 31 | (36) | (220) | (203) | |||
| Income tax expense (benefit) | (7) | (11) | 104 | (383) | 1 | |||
| Income (loss) from continuing operations: | (255) | 20 | 69 | (604) | (201) | |||
| Income (loss) before gain (loss) on sale of properties: | ✕ | 20 | 69 | (604) | (201) | |||
| Other undisclosed net income | 5 | |||||||
| Net income (loss): | (255) | 20 | 69 | (604) | (201) | |||
| Net income (loss) attributable to noncontrolling interest | 125 | (10) | 22 | 242 | 33 | |||
| Other undisclosed net income (loss) attributable to parent | (141) | 3 | 149 | |||||
| Net income (loss) attributable to parent: | (271) | 13 | 91 | (362) | (20) | |||
| Preferred stock dividends and other adjustments | (0) | (1) | ||||||
| Other undisclosed net income (loss) available to common stockholders, basic | 141 | (3) | ||||||
| Net income (loss) available to common stockholders, diluted: | (130) | 11 | 91 | (362) | (21) | |||
Comprehensive Income ($ in millions)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (255) | 20 | 69 | (604) | (201) | |||
| Comprehensive income (loss): | (255) | 20 | 69 | (604) | (201) | |||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 90 | (27) | 65 | 232 | 36 | |||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 70 | 34 | (84) | 19 | 142 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (95) | 27 | 50 | (353) | (23) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.